Related Experiment Video
Updated: Aug 16, 2026
09:01
Magnetic-, Acoustic-, and Optical-Triple-Responsive Microbubbles for Magnetic Hyperthermia and Pothotothermal Combination Cancer Therapy
Published on: May 22, 2020
Magnetically Navigated and PSMA/STEAP1 Dual-Targeted Nanoliposomes for NIR-II/MRI Imaging with
Jian-Xuan Sun1, Ye An2, Si-Han Zhang1
1Department and Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Research (Washington, D.C.)
|August 15, 2026
Summary
This study presents a novel nanoplatform for treating castration-resistant prostate cancer. It combines advanced imaging, targeted drug delivery, and immunotherapy to overcome treatment challenges and improve patient outcomes.
Area of Science:
- Oncology
- Nanotechnology
- Immunotherapy
Background:
- Castration-resistant prostate cancer (CRPC) presents significant treatment challenges due to tumor heterogeneity, drug toxicity, and therapy resistance.
- Current therapeutic strategies often lack specificity and efficacy in advanced stages of prostate cancer.
Purpose of the Study:
- To develop a multifunctional theranostic nanoplatform for precision treatment of CRPC.
- To integrate multimodal imaging, dual-targeted delivery, photothermal therapy, and immune activation into a single system.
Main Methods:
- Encapsulation of aggregation-induced emission luminogens and magnetic nanoparticles for multimodal imaging (NIRF and MRI).
- Dual-targeting strategy involving magnetic navigation and simultaneous targeting of six-transmembrane epithelial antigen of the prostate 1 and prostate specific membrane antigen (PSMA).
- Synergistic application of photothermal therapy and chemotherapy, coupled with immune activation (CD8+ T cells and macrophages).
Main Results:
- Achieved superior deep-tissue visualization through fused NIRF and MRI.
- Demonstrated effective, externally guided, and biologically specific delivery to both PSMA+ and PSMA- prostate cancer cells, addressing tumor heterogeneity.
- Showcased potent tumor growth inhibition, robust antitumor immune responses, and durable immunological memory.
- Exhibited enhanced tumor targeting specificity, improved imaging contrast, and minimal off-target toxicity in vitro and in vivo.
Conclusions:
- The developed multifunctional theranostic nanoplatform offers a promising approach for precision oncology in CRPC.
- This system effectively overcomes key challenges in CRPC treatment, including heterogeneity and resistance.
- The study highlights the translational potential of advanced nanotheranostics for clinical application in prostate cancer management.
